Letrozole is described as a nonsteroidal aromatase inhibitor that inhibits estrogen synthesis.
It is insoluble in water.
The medicine is considered as the first line treatment in postmenopausal women with hormone receptor positive and used for anti-estrogen therapy.
It is used in adjuvant treatment of rapid spreading hormone –dependant breast cancer.
Letrozole lowers the estrogen levels in post-menopausal women which reduces various types of breast tumors that need estrogen to grow in the body.
It is used in the neo-adjuvant treatment of post-menopausal women with hormone receptor positive and HER-2 –ve breast cancer. In this case, Chemotherapy does not suit and emergency surgery is not needed.
Monitor your luteinising hormone (LH), follicle stimulating hormone (FSH) and/or oestradiol levels before starting the medicine.
Letrozole contains lactose therefore it is restricted to patients with rare hereditary galactose intolerance problems, glucose-galactose malabsorption, and severe lactase deficiency.
Do not discontinue the course of medicine without your doctor’s advice, even if you feel good.